Making a Global
(Patient) Impact
Defence Therapeutics are Canadian scientific pioneers on a journey to uncover enhanced treatment solutions for future generations through biopharmaceutical innovations.
Leading the way with targeted science, strategic products and bold curiosity, we are uncovering micro and macro level methods, bringing catalytic change to future patients.
Making a Global
(Patient) Impact
Defence Therapeutics are Canadian scientific pioneers on a journey to uncover enhanced treatment solutions for future generations through biopharmaceutical innovations.
Leading the way with targeted science, strategic products and bold curiosity, we are uncovering micro and macro level methods, bringing catalytic change to future patients.
Innovating Pathways
to Success
First to develop a combined breakthrough, with precision and efficient cell nucleus drug delivery.
Proprietary and scalable technology targeted at viruses and infectious disease.
Problem-driven solutions confirming strong market potential and upside.
Fully owned assets to be capitalized via global licensing deals.
Exponential scaling potential through partner collaborations.
Proven ability as showcased via flourishing partner pubco’s: world-class and award-winning researchers, University level facilities, a leading global health care system and a sophisticated investor community.
Aggressive, accelerated growth model with two innovative and proprietary pathways to market.
01
ACCUM™ TECHNOLOGY
A scalable delivery platform with enormous multiplier effect offering a diversified investment opportunity.
02
VACCINE DEVELOPMENT
Numerous potential applications and indications through use of our catalytic and patented Accum™ Technology.
Innovating Pathways
to Success
First to develop a combined breakthrough, with precision and efficient cell nucleus drug delivery.
Proprietary and scalable technology targeted at viruses and infectious disease.
Problem-driven solutions confirming strong market potential and upside.
Fully owned assets to be capitalized via global licensing deals.
Exponential scaling potential through partner collaborations.
Proven ability as showcased via flourishing partner pubco’s: world-class and award-winning researchers, University level facilities, a leading global health care system and a sophisticated investor community.
Aggressive, accelerated growth model with two innovative and proprietary pathways to market.
01
ACCUM™ TECHNOLOGY
A scalable delivery platform with enormous multiplier effect offering a diversified investment opportunity.
02
VACCINE DEVELOPMENT
Numerous potential applications and indications through use of our catalytic and patented Accum™ Technology.
Platform Technology is the Path Forward
- Accum™ empowers vaccine development to become entirely scalable across multiple indications.
- This patented platform technology is supporting Defence Therapeutics vaccine development priorities:
• COVID-19 vaccine
• Cancer vaccines
- With drug delivery abilities at 10x over current ADC’s, our Accum™ platform is the perfect partner for current and future drug treatments.
- Accum™ is a global solution, and when paired with effective vaccines has the potential to become the therapeutic standard for human diseases.
Micro Innovations, Macro Opportunities
The biopharmaceutical space is ripe for innovation and investment to bring major disruption to the treatment of deathly viruses and infectious disease such as COVID-19:
SURGING DEMAND
Increasing elderly population, prevalence of chronic diseases and adoption of biopharmaceuticals globally are impacting demand.
INCREASED INNOVATION
Increasing number of clinical trials showcases the urgent requirement for new patient solutions. Innovative biopharmaceuticals hold the key.
ENHANCED TREATMENTS
ACCUM™ has a proven ability to deliver treatment drugs to diseased cells. Positive outcomes against targeted vaccines points to applications globally.
R&D INVESTMENT MOMENTUM
R&D investments for new platforms, formulations and products offering have the potential for big market impact and with it, returns.